We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B.
- Authors
Lampertico, Pietro; Viganò, Mauro; Facchetti, Floriana; Invernizzi, Federica; Aroldi, Adriana; Lunghi, Giovanna; Messa, Pier Giorgio; Colombo, Massimo
- Abstract
Background. To assess the long-term effectiveness and safety of adefovir (ADV) plus lamivudine (LMV) in LMV-resistant (R) kidney transplants with chronic hepatitis B, 11 such patients were treated with add-on ADV.Methods. Serum alanine aminotransferase, renal function and serum hepatitis B virus (HBV) DNA levels were assessed every 3 months; ADV mutations were searched for by INNO-LiPA HBV DR v2 assay.Results. During 36 months (12–48), nine patients cleared serum HBV DNA with a 3-year cumulative virological response rate of 88%, without the emergence of ADV mutations. ADV dose was reduced in six patients (55%) showing a decline of creatinine clearance, in the absence of proximal tubulopathy.Conclusions. In LMV-R kidney graft recipients, long-term add-on therapy with ADV is efficacious and safe with timely adaptation of ADV dose.
- Subjects
PHOSPHONIC acids; LAMIVUDINE; DRUG resistance; HOMOGRAFTS; HEPATITIS B; KIDNEY diseases; KIDNEY transplantation; AMINOTRANSFERASES
- Publication
Nephrology Dialysis Transplantation, 2011, Vol 26, Issue 6, p2037
- ISSN
0931-0509
- Publication type
Article
- DOI
10.1093/ndt/gfr174